) recently presented data on its cancer drug, Revlimid (as a
combination therapy) in patients suffering from various forms of
non-Hodgkin's lymphoma. Celgene presented data from two studies
at the international conference on malignant lymphoma held in
ALNYLAM PHARMA (ALNY): Free Stock Analysis
BIOGEN IDEC INC (BIIB): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.
One of the studies evaluated Revlimid in combination with the
RCHOP regimen as a first-line therapy in patients suffering from
diffuse large b-cell lymphoma (DLBCL) or follicular lymphoma
(grade 3b). We note that the RCHOP regimen includes
Biogen Idec Inc.
) Rituxan (rituximab).
Data from the study revealed an overall response rate of 98% (74%
patients achieved a complete response). The rate of progression
free survival witnessed in these patients was 66% at 18 months.
Data also revealed a progression free survival rate of 57% at 18
months for patients in the R-CHOP group. Data also revealed a
progression-free survival rate of 73% (at 18 months) in patients
without the germinal center b-cell version of DLBCL. The
comparable figure was 55% in patients with the germinal center
b-cell sub-type of the disease.
The other study is evaluating the combination of Revlimid and
Rituxan as a first-line therapy in patients with follicular
lymphoma. Data revealed that 92.6% patients treated with the
combination achieved an overall response rate of 92.6% and 72.2%
achieved a complete response. Successful development and
commercialization of Revlimid for treating various forms of
non-Hodgkin's lymphoma would further boost the sales potential of
Celgene's key growth driver.
We note that Revlimid is already approved for the myelodysplastic
syndromes (MDS) indication in many countries. The drug is also
approved in many countries across the globe in combination with
dexamethasone for treating multiple myeloma patients, who have
been treated at least once for the disease. We note that Revlimid
was approved in the EU for the MDS indication earlier in the
Celgene, a biopharmaceutical company, carries a Zacks Rank #3
Alnylam Pharmaceuticals, Inc.
) appears to be more attractive in the biopharma space with a
Zacks Rank #2 (Buy).